A clinical formulation indicated for Antifungals. Compound activity targets the synthesis of essential fungal cell membranes, which provides relief from persistent invasive fungal infections.
Developed to address life-threatening invasive fungal infections to alleviate systemic symptoms and mitigate pathogen spread in high-risk immunocompromised patients.
Mechanism of Action
Voriconazole interferes with the formation of the fungal cell wall. It blocks an enzyme that creates ergosterol, leading to structural gaps in the fungus that cause it to die.
Route of Administration
Oral
Onset Time
Variable; steady state in 24 hours
Duration
12 hours
Contraindications
Hypersensitivity to azole antifungals, Concurrent use with rifampin, carbamazepine, or quinidine
Severe Adverse Events
Severe liver damage, QT prolongation, Severe skin reactions (SJS), Hallucinations, Kidney failure
Information for Voriconazole is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
